ADMET and DMPK is a premier open-access journal published by IAPC PUBLISHING since 2013, focusing on the rapidly evolving fields of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) and DMPK (Drug Metabolism and Pharmacokinetics). Catering to researchers, professionals, and students in the realms of pharmacology, toxicology, and medicinal chemistry, this journal plays a crucial role in fostering innovation and collaboration within the interdisciplinary landscape of drug development. With an impressive Q1 ranking in Pharmacology, Toxicology and Pharmaceutics and ranking in the top percentiles across various categories such as Chemistry and Health, ADMET and DMPK provides a reputable platform for high-quality publications. Its global reach, complemented by its open-access model, ensures that valuable research is accessible to a wide audience. As we converge towards 2024, this journal remains dedicated to advancing knowledge and practices that shape the future of drug discovery and safety, making it an essential resource in the scientific community.

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

AAPS Journal, published by Springer in the United States, is a leading peer-reviewed journal dedicated to the advancement of research in the field of Pharmaceutical Sciences. With an impressive Q1 rank in its category and a position within the 81st percentile of Scopus rankings, it serves as a vital resource for researchers and professionals seeking to disseminate impactful findings and innovative methodologies. The journal publishes high-quality original research, review articles, and technical reports aimed at addressing the multifaceted challenges in pharmacology, toxicology, and pharmaceutics. Operating under an Open Access model, AAPS Journal ensures broad dissemination of knowledge, contributing to the enhanced visibility and accessibility of research outputs. With a publication window spanning from 1999 to 2024, it continues to shape the future of pharmaceutical research and its applications. Researchers, students, and industry professionals will find a valuable repository of cutting-edge knowledge in this esteemed journal.

Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.